金迪克(688670.SH)业绩快报：2025年度净亏损1.73亿元

Core Viewpoint - Jindike (688670.SH) reported a significant increase in revenue for the fiscal year 2025, but also faced substantial losses in net profit, indicating challenges in profitability despite revenue growth [1] Financial Performance - The company achieved an operating revenue of 113 million yuan, representing a year-on-year growth of 40.13% [1] - The net profit attributable to the parent company was -17.3 million yuan, reflecting a year-on-year increase in losses of 85.53% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -18 million yuan, showing a year-on-year increase in losses of 69.46% [1] Operational Insights - The revenue growth was primarily driven by early production scheduling, improved departmental coordination, and enhanced production efficiency [1] - The company accelerated the production and approval process for flu vaccines, addressing previous shipment delays [1] - Continuous optimization of marketing management and expansion into new markets contributed to increased product coverage [1]